

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Yues International Holdings Group Limited**

**樂氏國際控股集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1529)**

### **(1) APPOINTMENT OF EXECUTIVE DIRECTOR; AND (2) REMOVAL OF EXECUTIVE DIRECTOR**

#### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Yues International Holdings Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effective from 9 December 2023, Mr. Li Zhigang (“**Mr. Li**”) has been appointed as an executive Director.

The biographical details of Mr. Li are set out as follows:

Mr. Li, aged 41, is currently the executive director and general manager of Suzhou Institute of Traditional Chinese Medicine Co., Ltd.\* (蘇州中藥研究所有限公司) and a director of Jiangsu Kangda Testing Technology Co., Ltd. Mr. Li has served as an external tutor at Xi’an Jiaotong-Liverpool University since September 2021. Mr. Li worked in various positions at Suzhou Yuanchuang Pharmaceutical Research Co., Ltd.\* (蘇州源創藥物研究有限公司), Suzhou Youseen New Drug Development Co., Ltd.\* (蘇州玉森新藥開發有限公司), and ReneSola Ltd. (now known as Emeren Group Ltd) (NYSE: SOL).

Mr. Li passed the National Unified Legal Professional Qualification Examination\* (國家統一法律職業資格考試) of the People’s Republic of China (the “**PRC**”) in April 2021. Mr. Li is a non-practicing member of Shanghai Institute of Certified Public Accountants, a registered tax agent in the PRC, a certified internal auditor of the Institute of Internal Auditors and obtained the certification in risk management assurance from the Institute of Internal Auditors. He obtained a bachelor’s degree in engineering with major in biological engineering from Wuhan Technical Institute\* (武漢工業學院) (now known as Wuhan Polytechnic University\* (武漢輕工大學)) in June 2003 and a master’s degree in business administration from Xi’an Jiaotong University in June 2017.

Mr. Li has entered into a service agreement with the Company for an initial term of three years commencing from 9 December 2023, which is terminable by either party by giving to the other one month's prior notice in writing. Mr. Li shall hold office only until the next annual general meeting of the Company after his appointment and shall be subject to re-election at such meeting in accordance with the articles of association of the Company. Mr. Li is entitled to a director's remuneration of HK\$10,000 per month, which was approved by the Board on the recommendation of the remuneration committee and determined with reference to his general duties and responsibilities and the prevailing market conditions.

Save as disclosed, as at the date of this announcement, Mr. Li (i) does not hold any other position in the Company or its subsidiaries nor have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; (ii) does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); and (iii) did not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above, there are no other matters concerning the appointment of Mr. Li that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and there is no other information that needs to be disclosed pursuant to any of the requirement under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to welcome Mr. Li for joining the Company.

## **REMOVAL OF EXECUTIVE DIRECTOR**

The Board wishes to announce that Mr. Song Ruipeng ("**Mr. Song**") has been removed as an executive Director with effect from 9 December 2023 by notice in writing served on him signed by not less than three-fourths in number (or if that is not a round number, the nearest lower round number) of the Directors (including Mr. Song) then in office in accordance with article 105 (h) of the articles of association of the Company having considered Mr. Song's failure to discharge his duties and responsibilities in the capacity as an executive Director.

The Board considers that Mr. Song's removal as an executive Director would not have any significant adverse effect on the operations of the Company and its subsidiaries and is of the view that Mr. Song's above removal is in the interests of the Company and the Shareholders as a whole.

Save as disclosed above, the Board is not aware of any disagreements between Mr. Song and the Board and there are no other matters relating to Mr. Song's removal that needs to be brought to the attention of the Shareholders and the Stock Exchange.

By order of the Board  
**Yues International Holdings Group Limited**  
**Le Kang**  
*Chairman*

Hong Kong, 9 December 2023

*As at the date of this announcement, the Board consists of five executive Directors, Mr. Le Kang, Mr. Li Jiahao, Mr. Li Jiali, Mr. Du Yingyou and Mr. Li Zhigang, and four independent non-executive Directors, Mr. Yu Chun Man, Mr. Lau Wai Piu Patrick, Dr. Wang Yi and Mr. Chan Koon Yung.*

\* *For identification purpose only*